Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery
Key Takeaways
- GHRPs carry four primary documented risk categories: insulin resistance, IGF-1-mediated tumor promotion, hormonal imbalance, and sourcing contamination.
- Among the five agents reviewed, MK-677 shows the clearest glycemic risk, while Ipamorelin and Sermorelin demonstrate lower hormonal co-stimulation and metabolic impact.
- GHRPs elevate IGF-1 into ranges epidemiologically linked to increased prostate, breast, and colorectal cancer risk, so strict laboratory monitoring is required.
- Approximately one-third of unregulated peptides fail quality checks, with bacterial contamination found in 22% of user-reconstituted samples from online sources.
- Patients seeking safe, medically supervised GHRP protocols with batch-tested sourcing can schedule a consultation at Mirror Plastic Surgery to receive individualized lab monitoring and risk assessment.
How Growth Hormone Releasing Peptides Work
GHRPs are synthetic peptides that stimulate the pituitary gland to release your own growth hormone, either by mimicking ghrelin (ghrelin-receptor agonists) or by amplifying hypothalamic GHRH signaling. Elevated growth hormone then drives the liver to produce insulin-like growth factor 1 (IGF-1), which mediates most anabolic and metabolic effects.
The five agents most commonly used in clinical and self-administration settings differ in selectivity and potency:
- GHRP-2, a synthetic hexapeptide ghrelin mimetic, stimulates growth hormone with concurrent ACTH, cortisol, and prolactin elevation.
- GHRP-6, structurally similar to GHRP-2, produces a pronounced hunger response and comparable hormonal co-stimulation.
- Ipamorelin, a selective ghrelin-receptor agonist, stimulates growth hormone release with minimal cortisol or prolactin impact at standard doses.
- Sermorelin, a GHRH analog containing the first 29 amino acids of endogenous GHRH, preserves pituitary negative feedback and produces pulsatile rather than continuous growth hormone release.
- MK-677 (Ibutamoren), an orally active, non-peptide ghrelin mimetic with a long half-life, produces sustained growth hormone and IGF-1 elevation and carries the most documented metabolic risk in this class.
Metabolic Risks From GHRPs
Impaired glucose metabolism appears as the most consistent adverse signal across growth hormone secretagogue trials. A 2026 narrative review by Dominikowski et al. in Frontiers in Endocrinology identifies GHRP-2, GHRP-6, and Ipamorelin as agents linked to dysglycemia and other metabolic disturbances in clinical and self-administration contexts, along with prolactin and cortisol elevations.
MK-677 carries the clearest documented glycemic risk in human studies. In a two-year randomized controlled trial of 65 older adults aged 60–81, MK-677 at 25 mg/day increased fasting glucose by 0.3 mmol/L and reduced insulin sensitivity (Nass et al., 2008). A separate trial showed that eight weeks of MK-677 25 mg daily in 24 obese men impaired oral glucose tolerance at both two and eight weeks despite raising IGF-1 approximately 40% and increasing fat-free mass (Svensson et al., 1998).
For GH-axis peptides broadly, fasting glucose drifting into the 100–125 mg/dL range or HbA1c rising from 5.2% toward 5.7% signals the need to adjust or stop therapy. A HOMA-IR above 2.0 at baseline calls for discussion of lower doses and dietary adjustments before starting any growth hormone peptide protocol.
IGF-1 Elevation and Cancer Risk
IGF-1 elevation from GHRPs raises a theoretical oncologic concern based on epidemiologic data. A 2004 Lancet systematic review and meta-analysis by Renehan et al. of 21 studies involving 3,609 cancer cases found that higher circulating IGF-1 levels are associated with increased risk of prostate cancer (OR 1.49, 95% CI 1.14–1.95), premenopausal breast cancer (OR 1.65, 95% CI 1.26–2.08), and colorectal cancer (OR 1.49, 95% CI 1.11–2.01), with a dose-response relationship in which the strongest associations occurred in highest-versus-lowest IGF-1 quintile comparisons.
GHRPs produce IGF-1 elevations in the range where these associations appeared. MK-677 achieved a 72.9% increase in serum IGF-1 at 12 months in a 563-patient Alzheimer’s disease trial (Sevigny et al., 2008), while Svensson et al. (1998) found approximately 40% IGF-1 elevation after two months of MK-677 in obese men. No GHRP trial has been large enough or long enough to determine whether these increases translate into higher cancer incidence, and the Renehan meta-analysis measured endogenous rather than peptide-induced IGF-1 levels. This theoretical risk drives the practice of keeping IGF-1 within the age-adjusted normal range during any supervised protocol.
Hormonal and Cardiovascular Side Effects
Side-effect profiles differ meaningfully across individual GHRPs. Sermorelin side effects include injection-site reactions affecting about 16% of patients, while flushing, headache, dizziness, and altered taste each affect fewer than 10% (typically under 1% for subcutaneous use per the historical label). These effects usually resolve within the first two to three weeks at physiologic doses. Water retention and mild edema occur in 1–10% of patients and usually resolve within two to four weeks.
Ipamorelin does not meaningfully spike cortisol or prolactin at standard doses, per the foundational Raun et al. 1998 study in the European Journal of Endocrinology, giving it a cleaner side-effect profile than GHRP-6 and GHRP-2. Its most commonly reported effects are mild headache, occasional nausea at doses of 300 mcg and above, minor injection-site irritation, and infrequent mild water retention.
GHRP-2 and GHRP-6 carry additional hormonal burden. GHRP-2, GHRP-6, and Hexarelin can elevate prolactin and cortisol, requiring monitoring, whereas Ipamorelin and GHRH analogs such as Sermorelin do not. Acromegaly-like symptoms such as enlarged hands, feet, or facial bones represent a theoretical risk from long-term supraphysiologic growth hormone and IGF-1 exposure, but this scenario remains extremely unlikely with physiologic dosing of Sermorelin or Ipamorelin because negative feedback remains intact.
Quality-Control and Regulatory Problems With Peptides
A 2023 American Journal of Health-System Pharmacy analysis of peptides from unregulated online sources reported bacterial contamination in 22% of user-reconstituted samples. Research peptide suppliers in the grey market carry an estimated 15–25% post-reconstitution contamination rate, while underground lab or black-market resellers show a 30–40% estimated rate of contamination or mislabeling.
Independent laboratory testing confirms the scale of this quality problem. Independent testing laboratories report that about one-third of products analyzed failed basic quality checks for identity, purity, or quantity. Janoshik Analytical, a Czech Republic laboratory, receives 5,000 peptide samples per month for testing.
Peptide-by-Peptide Risk Comparison Table
Lab Monitoring Protocol at Mirror Plastic Surgery
The risk differences outlined in the comparison table above highlight why systematic laboratory monitoring is the primary tool for detecting and mitigating GHRP-related risks before they become clinically significant. Mirror Plastic Surgery’s concierge model, led by Ellie Pranckevicius, FNP-BC, structures monitoring around three time points.
Baseline (before initiating any protocol):
- IGF-1 (age-specific reference ranges: 116–358 ng/mL ages 20–30; 88–246 ng/mL ages 30–40; 71–200 ng/mL ages 40–50; 55–166 ng/mL ages 50+)
- Fasting glucose and fasting insulin (HOMA-IR calculated; values above 2.0 warrant protocol modification)
- HbA1c
- Full lipid panel including ApoB
- Comprehensive metabolic panel (CMP) and CBC with differential
- Full thyroid panel: TSH, Free T3, Free T4
- Morning cortisol (drawn fasted, 7–9 AM)
- Sex hormone panel (total and free testosterone, estradiol, LH, FSH, SHBG, DHEA-S)
- Prolactin (required for GHRP-2 and GHRP-6 protocols)
Early monitoring (weeks 4–8):
- IGF-1, fasting glucose, and fasting insulin to confirm GH response and provide an early metabolic safety check
- Prolactin repeat if GHRP-2 or GHRP-6 is in use and symptoms have emerged
- AM cortisol repeat for GHRP-2 or GHRP-6 protocols at advanced dosing frequency
Quarterly (weeks 12–16 and every three months thereafter):
- IGF-1, fasting glucose, fasting insulin, HbA1c
- Full lipid panel and CMP
- Thyroid panel if abnormal at baseline or symptoms emerge
- PSA for men over 50 given the theoretical IGF-1 and prostate cancer relationship
Therapy aims to restore IGF-1 to the mid-to-upper age-adjusted normal range; sustained levels above 300–400 ng/mL have been associated with increased cell proliferation risk and are not indicated. Ellie’s ICU-trained clinical background and 24/7 concierge availability mean that abnormal results trigger immediate protocol review rather than waiting for a scheduled appointment.
Book an appointment with Ellie to receive a baseline lab panel and a protocol built around your specific metabolic profile before starting any GHRP therapy.
When GHRPs Should Be Avoided
Certain clinical conditions represent absolute or relative contraindications to GHRP use. The following red flags, drawn from cited clinical literature, require either deferral of therapy or specialist clearance:
- Active malignancy or history of GH-sensitive cancers (pituitary, breast, prostate)
- Uncontrolled diabetes (HbA1c >9%)
- Severe liver disease or untreated hypothyroidism
- Pregnancy or breastfeeding
- Fasting glucose >126 mg/dL, HbA1c >6.5%, IGF-1 >1.5× the age-appropriate upper reference range, prolactin >2× ULN with symptoms, or liver enzymes >3× ULN during an active protocol each requires immediate cessation
- Severe heart or kidney disease
Supervised vs. Unsupervised Peptide Sourcing
The sourcing gap between practitioner-dispensed and online-purchased peptides is large and clinically meaningful. Approximately one-third of products tested by independent laboratories fail basic quality checks for identity, purity, or quantity, with this failure rate unchanged over more than a year of data. A failed product may be inert and deliver no therapeutic effect, or it may be contaminated with organisms capable of causing sepsis, or mislabeled at a dose that produces toxicity.
Mirror Plastic Surgery sources peptides exclusively from suppliers with documented batch testing, providing verified identity, purity above 98%, and accurate dosing. This sourcing is paired with Ellie Pranckevicius’s in-depth consultation process, which includes review of medical history, current medications, and lab panels before any protocol begins. Patients receive detailed reconstitution and administration instructions, often with video demonstrations, and maintain direct 24/7 text access to Ellie throughout their protocol. This level of oversight does not exist with online sourcing.
Book an appointment with Ellie to access batch-tested peptides and a medically supervised protocol tailored to your lab results and health history.
Key Takeaways on GHRP Safety
Four primary risk categories apply to all GHRPs:
- Insulin resistance, most consistently documented with MK-677 and present across the class, requires fasting glucose, fasting insulin, and HbA1c monitoring at baseline and quarterly.
- IGF-1-mediated tumor promotion, supported by epidemiologic associations for prostate, breast, and colorectal cancer at elevated IGF-1 levels, remains a theoretical but serious concern that calls for strict IGF-1 monitoring.
- Hormonal imbalance, with GHRP-2 and GHRP-6 elevating cortisol and prolactin and all agents carrying theoretical acromegaly risk at supraphysiologic doses, appears lower with Ipamorelin and Sermorelin.
- Sourcing contamination, reflected in approximately one-third of unregulated products failing quality checks and a 22% bacterial contamination rate in reconstituted samples from online sources, decreases substantially with batch-tested, practitioner-dispensed sourcing.
Laboratory-guided, medically supervised protocols with verified sourcing represent the standard of care for GHRP use.
Book an appointment with Ellie at Mirror Plastic Surgery in St. Petersburg, Florida, to begin with a comprehensive lab panel, a personalized risk assessment, and a protocol built for your specific physiology.
Frequently Asked Questions
What is the difference in risk between Sermorelin and MK-677?
Sermorelin and MK-677 differ substantially in their metabolic risk profiles. Sermorelin is a GHRH analog that stimulates pulsatile, physiologic growth hormone release and preserves pituitary negative feedback, so IGF-1 elevation remains self-limiting. Its glucose effects are uncommon and typically mild at physiologic doses. MK-677, by contrast, is an orally active ghrelin mimetic with a long half-life that produces sustained growth hormone and IGF-1 elevation. Clinical trials have documented measurable increases in fasting glucose and impaired oral glucose tolerance at the standard 25 mg/day dose, making it the agent with the clearest documented insulin resistance risk in this class. Individuals with prediabetes, elevated HOMA-IR, or a family history of type 2 diabetes face greater metabolic risk with MK-677 than with Sermorelin or Ipamorelin and require closer glucose monitoring if MK-677 is selected.
How does IGF-1 elevation from GHRPs relate to cancer risk, and how is it managed at Mirror Plastic Surgery?
The oncologic concern comes from epidemiologic data linking higher circulating IGF-1 levels to increased odds of prostate, breast, and colorectal cancer. GHRPs can raise IGF-1 into these higher ranges, although no GHRP clinical trial has been large or long enough to determine whether such increases translate into higher cancer incidence. The risk therefore remains theoretical but not dismissible. At Mirror Plastic Surgery, Ellie Pranckevicius manages this risk by targeting IGF-1 restoration to the mid-to-upper age-adjusted normal range rather than pushing levels above it. IGF-1 is measured at baseline, at weeks 4–8, and quarterly thereafter. If IGF-1 exceeds the upper limit of the age-appropriate reference range, the protocol is adjusted or paused. Men over 50 also receive quarterly PSA monitoring given the sensitivity of prostate biology to IGF-1. Individuals with a personal or family history of IGF-1-sensitive cancers receive individualized evaluation, and active malignancy remains a contraindication to initiating any GHRP protocol.
Why does sourcing matter so much for peptide safety, and how does Mirror Plastic Surgery address it?
Peptides are not FDA-regulated as drugs when compounded or sold through research channels, so no mandatory pre-market testing exists for identity, purity, or sterility. Independent laboratory data show that approximately one-third of products purchased from unregulated online sources fail basic quality checks, and bacterial contamination has been found in roughly 22% of user-reconstituted samples from these sources. A contaminated or mislabeled product can produce no therapeutic effect, cause a localized infection, or in serious cases lead to systemic sepsis. Mirror Plastic Surgery sources exclusively from suppliers who conduct rigorous batch testing, providing documented verification of identity, purity above 98%, and accurate dosing for every lot. Patients receive their peptides through a medically supervised dispensing process rather than purchasing from an unverified online retailer, and Ellie Pranckevicius provides detailed reconstitution and administration guidance to minimize handling errors that can introduce contamination after dispensing.
What lab results would cause Ellie to pause or stop a GHRP protocol?
Several laboratory findings trigger immediate protocol review or cessation. Fasting glucose above 126 mg/dL or HbA1c above 6.5% indicates frank diabetes and requires stopping the protocol and addressing glycemic control before reconsidering peptide therapy. IGF-1 exceeding 1.5 times the age-appropriate upper reference range warrants dose reduction or pause because of theoretical mitogenic risk. Prolactin above twice the upper limit of normal with symptoms such as libido changes or gynecomastia, most relevant for GHRP-2 and GHRP-6 users, requires switching agents or reducing dose. Liver enzymes above three times the upper limit of normal require cessation and hepatic evaluation. Fasting glucose drifting into the 100–125 mg/dL range or fasting insulin above 15 μIU/mL signals developing insulin resistance and prompts dose adjustment before values reach diagnostic thresholds. Because Ellie maintains 24/7 direct text access with every patient, abnormal results receive attention immediately rather than at the next scheduled visit.
Can GHRPs be used safely if I have prediabetes or a history of elevated blood sugar?
Prediabetes functions as a relative contraindication rather than an absolute one and calls for a more conservative approach. Growth hormone elevation from any secretagogue transiently worsens insulin sensitivity, and individuals with already impaired glucose metabolism face a higher baseline risk of progression. Before starting a GHRP protocol in this context, Ellie reviews fasting glucose, fasting insulin, HbA1c, and HOMA-IR. A HOMA-IR above 2.0 at baseline leads to discussion of lower starting doses, dietary modifications, and more frequent early monitoring. Sermorelin or Ipamorelin, agents with lower and more self-limiting IGF-1 elevation, are generally preferred over MK-677 in this population. Fasting glucose is monitored weekly in the early weeks of the protocol rather than at the standard four-to-six-week interval. If glucose trends upward despite dose adjustment, the protocol is paused. Uncontrolled diabetes with HbA1c above 9% remains a contraindication to initiating any GHRP therapy.
Medical Disclaimer: The information provided in this article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Growth hormone releasing peptides are not FDA-approved drugs for the indications discussed. Individual risks vary based on personal health history, concurrent medications, and laboratory values. Consult a qualified, licensed healthcare provider before initiating any peptide therapy. Mirror Plastic Surgery’s peptide protocols are provided under the supervision of a board-certified nurse practitioner following individualized clinical assessment.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
